益气固本汤联合化疗治疗晚期非小细胞肺癌患者临床研究

Clinical Study of Yiqi Guben Decoction(益气固本汤)Combined with Chemotherapy for Advanced Patients with Non-small Cell Lung Cancer

目的探讨益气固本汤联合化疗在晚期非小细胞肺癌患者中的应用。方法研究对象:淮安市淮安医院收治的晚期非小细胞肺癌患者,样本量:94例,选例时间:2019年3月—2021年3月,将其划分为观察组、对照组各47例。给予对照组多西他赛联合顺铂(DC)方案化疗,在上述方案基础上给予观察组益气固本汤治疗,均治疗2个周期,随访1年。对比两组治疗后近期疗效,治疗前后血清肿瘤标志物水平、免疫功能、肺癌主要症状评分,治疗期间不良反应,1年后生存率。结果观察组治疗后近期总有效率57.45%高于对照组的23.40%;治疗后,两组血清人鳞状细胞癌相关抗原(SCCAg)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)及糖链抗原19-9(CA19-9)、CD8^(+)水平、肺癌各个主要症状评分与治疗前相比较均降低,观察组较对照组更低,CD3^(+)、CD4^(+)水平、CD4^(+)/CD8^(+)值则升高,观察组高于对照组;观察组治疗期间不良反应总发生率17.02%低于对照组38.30%;治疗后1年对照组总生存率63.83%,低于观察组82.98%,差异有统计学意义(P<0.05)。结论益气固本汤结合化疗治疗晚期非小细胞肺癌患者具有较显著的临床疗效以及较高的后期生存率,可改善肺癌主要症状及免疫功能,同时对机体的血清肿瘤标志物水平有明显抑制作用,整体安全性高。

Objective To investigate the application of Yiqi Guben Decoction(益气固本汤)combined with chemotherapy in patients with non-small cell lung cancer.Methods Subjects:Patients with non-small cell lung cancer admitted to Huaian hospital,sample size:94 cases,selected from March 2019 to March 2021,were divided into the observation group and the control group,47 cases each.The control group was given docetaxel combined with cisplatin(DC)chemotherapy,and the observation group was given Yiqi Guben Decoction on the basis of the above treatment,both of which lasted for 2 cycles and were followed up for 1 year.The short-term efficacy,serum tumor marker level,immune function,main symptom score of lung cancer before and after treatment,toxicity and side effects during treatment,and 1-year survival rate of the two groups were compared.Results The total effective rate of observation group was 57.45%higher than that of control group(23.40%).After treatment,serum levels of human squamous cell carcinomaassociated antigen(SCCAg),neuron-specific enolase(NSE),carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9),CD8^(+),and scores of lung cancer main symptoms in both groups decreased compared with before treatment,and the observation group was lower than the control group.The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)increased,and the observation group was higher than the control group.The total incidence of toxicity and side effects in the observation group was 17.02%lower than that in the control group,which was 38.30%.One year after treatment,the overall survival rate of the control group was 63.83%,which was lower than that of the observation group 82.98%(P<0.05),indicating a significant difference in the calculated data.Conclusion The application of Yiqi Guben Decoction combined with chemotherapy in patients with advanced non-small cell lung cancer has a significant clinical therapeutic effect and survival rate in the later stage,which can improve the main symptoms and immune function of lung cancer,and has a significant inhibitory effect on the level of serum tumor markers in the body,with high overall safety.